close

Agreements

1 2 3 248
Number of results: 4957

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2018-12-04 Boehringer Ingelheim (Germany) Domain Therapeutics (France) orphan G Protein-Coupled Receptors (GPCRs) research - licensing CNS diseases Licensing agreement
2018-12-04 Lundbeck (Denmark) resignation Resignation
2018-11-29 BMS (USA - NY) the Francis Crick Institute (UK) Cancer Research UK (UK) RUBICON, a rule book and immune atlas for combination therapy lung cancer collaboration Cancer - Oncology Collaboration agreement
2018-11-26 Intrasense (France) 12 Sigma Technologies (USA - CA) ?Discover Lung Nodule, Artificial Intelligence-based Computer Aided Diagnostics (CAD) solutions lung cancer collaboration Technology - Services Collaboration agreement
2018-11-26 RegenXBio (USA - MD) Rocket Pharmaceuticals (USA - NY) NAV AAV9 vector and two additional NAV AAV vectors Danon disease licensing Rare diseases - Genetic diseases - Cardiovascular diseases - Neuromuscular diseases Licensing agreement
2018-11-20 Santhera Pharmaceuticals (Switzerland) Idorsia (Switzerland) VBP15 (vamorolone) Duchenne muscular dystrophy licensing   Rare diseases - Genetic diseases - Neuromuscular diseases Licensing agreement
2018-11-14 Nektar Therapeutics (USA - CA) vice president nomination Cancer - Oncology Nomination
2018-11-12 Integragen (France) Google Cloud (USA - CA) SIRIUS™ and MERCURY™ collaboration Technology - Services Collaboration agreement
2018-11-10 Abbvie (USA - IL) Sandoz (Switzerland)
  • intellectual property relating to Humira®
plaque psoriasis, rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, polyarticular juvenile idiopathic arthritis, active enthesitis-related arthritis, hidradenitis suppurativa, non-infectious uveitis licensing
  • biosimilar/monoclonal antibody/TNF alpha inhibitor. Adalimumab is a monoclonal antibody that binds specifically to TNF alpha and blocks its interaction with  cell surface TNF receptors. It is used to treat many conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Dermatological diseases Licensing agreement
2018-11-05 Actelion (Switzerland), now Idorsia (Switzerland) ReveraGen BioPharma (USA - MD) vamorolone Duchenne muscular dystrophy licensing Rare diseases - Genetic diseases - Neuromuscular diseases Licensing agreement
2018-11-01 Denali Therapeutics (USA - CA) Sanofi (France) RIPK1 inhibitor molecules including DNL747 and DNL758 Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseases as rheumatoid arthritis and psoriasis. development - licensing - commercialisation Neurodegenerative diseases - Inflammatory diseases - Autoimmune diseases Development agreement
2018-10-31 Novo Nordisk (Denmark) Strongbridge Biopharma (Ireland) US and Canadian rights to Macrilen™ (macimorelin)   adult growth hormone deficiency (AGHD) licensing Rare diseases - Endocrine diseases - Hormonal diseases Licensing agreement
2018-10-31 MeiraGTx (USA - NY) National Institute of Dental and Craniofacial Research (NIDCR) (USA) AAV-AQP1 Sjögren’s syndrome and associated xerostomia or xerophthalmia licensing Rare diseases Licensing agreement
2018-10-30 Transgene (France) NEC (Japan) myvac™  and Neoantigen Prediction System solid tumors including ovarian cancer and HPV-negative head and neck cancer collaboration Cancer - Oncology Collaboration agreement
2018-10-29 Ionis Pharmaceuticals (USA - CA) ProQR Therapeutics (The Netherlands) QR-1123 (formerly “IONIS-RHO-2.5Rx”) autosomal dominant retinitis pigmentosa caused by the P23H mutation in the rhodopsin (RHO) gene (P23H adRP) licensing Rare diseases - Genetic diseases - Ophtalmological diseases Licensing agreement
2018-10-25 89Bio (USA - CA) CEO -CSO - COO - CBO - member of the board of directors nomination Hepatic diseases - Liver diseases Restructuring
2018-10-25 Disarm Therapeutics (USA - MA) member of the board of directors nomination Neurological diseases - Neurodegenerative diseases Nomination
2018-10-23 Cryoport (USA - CA) global logistics center in Livingston opening of new premises Technology - Services Opening of new premises
2018-10-22 RegenXBio (USA - MD) Ultragenyx Pharmaceutical (USA - CA) adeno-associated virus (AAV) vectors, including AAV9 CDKL5 deficiency disorder licensing Rare diseases - Genetic diseases - Neurological diseases Licensing agreement
2018-10-18 Abbvie (USA - IL) Fresenius Kabi (Germany) MSB11022 - biosimilar version of Humira® (adalimumab) licensing Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases Licensing agreement